Project Grant R21MH143206
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded a $433,125 Project Grant to the University of California, Los Angeles under the Mental Health Research Grants program (CFDA 93.242) for a two-year project period from September 18, 2025 to September 17, 2027. This research initiative investigates the asymmetrical development of early B cell factor gene 1 (EBF1)-positive cells in the central amygdala and their functional consequences in emotion regulation and...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Leland Stanford Junior University a $1,066,793 Project Grant under the Mental Health Research Grants program (CFDA 93.242) effective April 1, 2026 through January 31, 2028. This research initiative focuses on developing and validating a personalized intermittent theta-burst stimulation (ITBS) protocol to improve treatment outcomes for patients with treatment-resistant depression (TRD). The project utilizes...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of California, Los Angeles a Project Grant totaling $424,433 (awarded March 1, 2026; completion December 31, 2029) under the Mental Health Research Grants program (CFDA 93.242) to develop practical guidance and implementation tools for enhancing participant engagement in brain-computer interface (BCI) early feasibility studies. The project will produce two primary deliverables: a comprehensive...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded a $408,843 Project Grant to the University of California, Los Angeles on April 25, 2026, under the Mental Health Research Grants program (CFDA 93.242). The research project, titled "Autonomic Regulation of Brain Function and Cognition in Patients with First-Episode Schizophrenia and Healthy Individuals," investigates the mechanistic relationship between autonomic nervous system (ANS) dysfunction and...
- Federal Grant Award Summary The Laureate Institute for Brain Research, Inc. received a $514,178 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), effective July 1, 2025, through April 30, 2030. The award funds a five-year research initiative investigating the mechanistic relationships between brain circuits and negative valence system behaviors in treatment-resistant depression (TRD) using low-intensity...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded UCLA a Project Grant totaling $118,404.00 under the Mental Health Research Grants program (CFDA 93.242) for the period July 1, 2026 through June 30, 2028. This K99/R00 award supports research to identify dynamic functional network biomarkers associated with emotion regulation (ER) flexibility in internalizing disorders, including depression, anxiety, and post-traumatic stress disorder. The research employs dynamic...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded Washington University a Project Grant totaling $284,333 under the Mental Health Research Grants program (CFDA 93.242) on August 4, 2025, for research on mechanism-based dose titration strategies to modify brain electrophysiology during antidepressant therapy for treatment-resistant depression (TRD). The research will be conducted through June 30, 2029, and focuses on developing personalized medicine approaches...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded Northwestern University a $400,000 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to advance understanding of seizure networks in electroconvulsive therapy (ECT). The award, initiated May 1, 2026, with an ultimate completion date of January 31, 2031, funds research to elucidate how therapeutic seizures induced during ECT improve symptoms of severe treatment-refractory...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded $818,253 to The Regents of the University of California, San Francisco under the Mental Health Research Grants program (CFDA 93.242) beginning July 1, 2025, and extending through April 30, 2030. This Project Grant supports a five-year research investigation examining neuromodulatory system abnormalities in late-life depression (LLD), with specific focus on the associations between structural and functional brain...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded $394,200 to the Research Foundation For Mental Hygiene, Inc. (through its New York State Psychiatric Institute division) under the Mental Health Research Grants program (CFDA 93.242) on August 1, 2025, for a five-year project period extending through July 31, 2030. This Project Grant funds a clinical research study examining the role of the anterior hippocampus in major depressive disorder (MDD) pathogenesis....
The National Institute of Mental Health (NIMH) awarded the University of California, Los Angeles a $433,125 Project Grant under the Mental Health Research Grants program (CFDA 93.242) effective June 15, 2026, with a completion date of June 14, 2028. This high-risk/high-reward research initiative (R21 mechanism) will investigate cell-free DNA (cfDNA) as a biomarker for electroconvulsive therapy (ECT) outcomes in patients with treatment-resistant depression (TRD). The project leverages an existing NIMH-funded longitudinal study infrastructure to examine the dynamics of circulating cfDNA—short DNA fragments released into the bloodstream from cells throughout the body—in the context of ECT treatment responses, with the objective of understanding the physiological mechanisms underlying both the therapeutic and cognitive side effects of ECT. The research will advance understanding of ECT's antidepressant mechanisms by analyzing inflammatory responses and neurotrophic processes that may be reflected in cfDNA profiles. By identifying biomarkers associated with treatment efficacy and adverse cognitive outcomes, this work aims to inform strategies for optimizing ECT protocols to maximize therapeutic benefit while minimizing cognitive risks in patients with treatment-resistant depression who are otherwise inadequately served by first-line pharmacotherapies.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $433.1k | 6/10/26 |